Introduction:Heart failure is a major public health issue with a prevalence of about 26 million people worldwide.Reduced nitric oxide availability,lower soluble guanylate cyclase(sGC)activity,and decreased cyclic guan...Introduction:Heart failure is a major public health issue with a prevalence of about 26 million people worldwide.Reduced nitric oxide availability,lower soluble guanylate cyclase(sGC)activity,and decreased cyclic guanosine monophosphate(cGMP)production are the causes of HF's development.Vericiguat prescribed under the brand name Verquvo was approved by U.S.Food and Drug Administration(FDA)in January 2021.It is a novel agent and the first sGC stimulator which helps to treat patients suffering from heart failure with reduced ejection fraction(HFrEF).Objective:The mechanism of action(cGMP pathway)of vericiguat,its clinical trials,its use in the treatment of heart failure,and its possible future aspects in therapeutic recommendations are all covered in this review.It will also raise awareness amongst healthcare professionals about the pharmacokinetic and pharmacodynamic parameters,dosing,administration,and drug-related problems of this new drug.Methods:Various databases for drug review were used in this review like PubMed,Medline,Google scholar,Drug bank,U.s.FDA,Medscape,and European society of cardiology guidelines.A total of 58 articles were screened out of which 39 articles were included in this review.Results:This review discusses vericiguat's mechanism of action(cGMP pathway),clinical studies,application in the treatment of heart failure,and potential future considerations in therapeutic recommendations.It will also educate healthcare professionals about the new drug's pharmacokinetics and pharmacodynamics,dose,administration,and drug-related problems.Conclusion:After hospitalization for HFrEF,the 5-year survival rate is just 25%,and disease morbidity and death are stil significant.As adjunctive therapy for individuals with heart failure and a low ejection fraction,vericiguat has a moderate level of effectiveness.Vericiguat's efficacy as an adjunct therapy to different drugs used to cure HF has to be further investigated.Vericiguat's safety and dosage in patients who have severe renal or hepatic illness need to be studied further.展开更多
BACKGROUND Heart failure(HF),an end-stage manifestation of various cardiac diseases,poses an enormous economic and health burden on society.Vericiguat may be an effective drug in the treatment of HF.AIM To explore by ...BACKGROUND Heart failure(HF),an end-stage manifestation of various cardiac diseases,poses an enormous economic and health burden on society.Vericiguat may be an effective drug in the treatment of HF.AIM To explore by meta-analysis the efficacy and safety of Vericiguat in treating chronic heart failure.METHODS Databases,including PubMed,EMBASE,Web of Science,and Cochrane Library,were searched to collect all published randomized controlled trials(RCTs)on Vericiguat treatment of chronic heart failure from the earliest electronic records to those published in March 2023.Two investigators independently screened the literature according to inclusion and exclusion criteria,evaluated the quality of the studies,and extracted valid data before conducting a meta-analysis using RevMan5.4.RESULTS Four RCTs with 5919 patients were included,and the meta-analysis showed that treatment with 10 mg Vericiguat reduced the incidence of the primary endpoint(a composite of cardiovascular mortality and first heart-failure-related hospital-ization)in patients with chronic heart failure compared to placebo[relative risk(RR)=0.91,95%confidence interval(CI):0.85–0.98,P=0.01],and reduced the incidence of heart-failure-related hospitalization(RR=0.92,95%CI:0.84–1.00,P=0.05).However,for the incidence of cardiovascular and all-cause death,there were no significant differences between the Vericiguat and placebo groups.In addition,the two groups did not show significant differences in blood pressure,heart rate,and Kansas Cardiomyopathy Questionnaire physical limitation score.In terms of safety,10 mg Vericiguat did not increase the risk of adverse effects in patients with chronic heart failure.Vericiguat may increase the risk of symp-tomatic hypotension(RR=1.17,95%CI:0.98–1.39,P=0.08)and syncope(RR=1.18,95%CI:0.90–1.55,P=0.24),but not significantly.CONCLUSION Vericiguat(10 mg)was more effective than placebo in treating patients with chronic heart failure and had a better safety profile.展开更多
文摘Introduction:Heart failure is a major public health issue with a prevalence of about 26 million people worldwide.Reduced nitric oxide availability,lower soluble guanylate cyclase(sGC)activity,and decreased cyclic guanosine monophosphate(cGMP)production are the causes of HF's development.Vericiguat prescribed under the brand name Verquvo was approved by U.S.Food and Drug Administration(FDA)in January 2021.It is a novel agent and the first sGC stimulator which helps to treat patients suffering from heart failure with reduced ejection fraction(HFrEF).Objective:The mechanism of action(cGMP pathway)of vericiguat,its clinical trials,its use in the treatment of heart failure,and its possible future aspects in therapeutic recommendations are all covered in this review.It will also raise awareness amongst healthcare professionals about the pharmacokinetic and pharmacodynamic parameters,dosing,administration,and drug-related problems of this new drug.Methods:Various databases for drug review were used in this review like PubMed,Medline,Google scholar,Drug bank,U.s.FDA,Medscape,and European society of cardiology guidelines.A total of 58 articles were screened out of which 39 articles were included in this review.Results:This review discusses vericiguat's mechanism of action(cGMP pathway),clinical studies,application in the treatment of heart failure,and potential future considerations in therapeutic recommendations.It will also educate healthcare professionals about the new drug's pharmacokinetics and pharmacodynamics,dose,administration,and drug-related problems.Conclusion:After hospitalization for HFrEF,the 5-year survival rate is just 25%,and disease morbidity and death are stil significant.As adjunctive therapy for individuals with heart failure and a low ejection fraction,vericiguat has a moderate level of effectiveness.Vericiguat's efficacy as an adjunct therapy to different drugs used to cure HF has to be further investigated.Vericiguat's safety and dosage in patients who have severe renal or hepatic illness need to be studied further.
基金Key Research and Development projects in Jiangxi Province,No.20223BBG71010National Natural Science Foundation of China,No.81960058.
文摘BACKGROUND Heart failure(HF),an end-stage manifestation of various cardiac diseases,poses an enormous economic and health burden on society.Vericiguat may be an effective drug in the treatment of HF.AIM To explore by meta-analysis the efficacy and safety of Vericiguat in treating chronic heart failure.METHODS Databases,including PubMed,EMBASE,Web of Science,and Cochrane Library,were searched to collect all published randomized controlled trials(RCTs)on Vericiguat treatment of chronic heart failure from the earliest electronic records to those published in March 2023.Two investigators independently screened the literature according to inclusion and exclusion criteria,evaluated the quality of the studies,and extracted valid data before conducting a meta-analysis using RevMan5.4.RESULTS Four RCTs with 5919 patients were included,and the meta-analysis showed that treatment with 10 mg Vericiguat reduced the incidence of the primary endpoint(a composite of cardiovascular mortality and first heart-failure-related hospital-ization)in patients with chronic heart failure compared to placebo[relative risk(RR)=0.91,95%confidence interval(CI):0.85–0.98,P=0.01],and reduced the incidence of heart-failure-related hospitalization(RR=0.92,95%CI:0.84–1.00,P=0.05).However,for the incidence of cardiovascular and all-cause death,there were no significant differences between the Vericiguat and placebo groups.In addition,the two groups did not show significant differences in blood pressure,heart rate,and Kansas Cardiomyopathy Questionnaire physical limitation score.In terms of safety,10 mg Vericiguat did not increase the risk of adverse effects in patients with chronic heart failure.Vericiguat may increase the risk of symp-tomatic hypotension(RR=1.17,95%CI:0.98–1.39,P=0.08)and syncope(RR=1.18,95%CI:0.90–1.55,P=0.24),but not significantly.CONCLUSION Vericiguat(10 mg)was more effective than placebo in treating patients with chronic heart failure and had a better safety profile.
